Zymeworks To Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
We’re excited to share further details on our upcoming presentations at the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) Conference taking place in Barcelona on October 23-25, 2024. Oral Presentation: Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and […]
Dr. Raffaele Colombo Honored as a PharmaVoice 100 Winner
Zymeworks is thrilled to announce that Dr. Raffaele Colombo has been honored as a PharmaVoice 100 winner. This annual list recognizes the most inspiring people in the life sciences industry. Dr. Colombo has been instrumental in the advancement of Zymeworks’ wholly-owned pipeline, leveraging his experience and knowledge towards the development of a portfolio of novel […]
Zymeworks Announces Upcoming Scientific Presentation at the Society for Immunotherapy of Cancer Annual Meeting
We are excited to announce a poster presentation highlighting preclinical data for ZW171 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas. Presentation Details Title: Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting […]
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
Zymeworks Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy as first-line treatment for patients with HER2-expressing advanced or metastatic gastroesophageal adenocarcinoma (mGEA). Data from […]
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ESMO 2024
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, presentations on new and updated data from trials of zanidatamab at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in Barcelona, Spain. New and updated data with longer follow-up, including overall survival findings, will be presented from an ongoing […]
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
